Chi Fung Lee1, Juan D Chavez1, Lorena Garcia-Menendez1, Yongseon Choi1, Nathan D Roe1, Ying Ann Chiao1, John S Edgar1, Young Ah Goo1, David R Goodlett1, James E Bruce1, Rong Tian2. 1. From Mitochondria and Metabolism Center (C.F.L., L.G.-M., Y.C., N.D.R., R.T.), Department of Anesthesiology and Pain Medicine (C.F.L., L.G.-M, Y.C., N.D.R., R.T.), Department of Genome Sciences (J.D.C., J.E.B.), Department of Pathology (Y.A.C.), and Department of Medicinal Chemistry (J.S.E., Y.A.G., D.R.G.), University of Washington, Seattle, WA. 2. From Mitochondria and Metabolism Center (C.F.L., L.G.-M., Y.C., N.D.R., R.T.), Department of Anesthesiology and Pain Medicine (C.F.L., L.G.-M, Y.C., N.D.R., R.T.), Department of Genome Sciences (J.D.C., J.E.B.), Department of Pathology (Y.A.C.), and Department of Medicinal Chemistry (J.S.E., Y.A.G., D.R.G.), University of Washington, Seattle, WA. rongtian@u.washington.edu.
Abstract
BACKGROUND: Impairments of mitochondrial function in the heart are linked intricately to the development of heart failure, but there is no therapy for mitochondrial dysfunction. METHODS: We assessed the reduced/oxidized ratio of nicotinamide adenine dinucleotide (NADH/NAD(+) ratio) and protein acetylation in the failing heart. Proteome and acetylome analyses were followed by docking calculation, mutagenesis, and mitochondrial calcium uptake assays to determine the functional role of specific acetylation sites. The therapeutic effects of normalizing mitochondrial protein acetylation by expanding the NAD(+) pool also were tested. RESULTS: Increased NADH/NAD(+) and protein hyperacetylation, previously observed in genetic models of defective mitochondrial function, also are present in human failing hearts as well as in mouse hearts with pathologic hypertrophy. Elevation of NAD(+) levels by stimulating the NAD(+) salvage pathway suppressed mitochondrial protein hyperacetylation and cardiac hypertrophy, and improved cardiac function in responses to stresses. Acetylome analysis identified a subpopulation of mitochondrial proteins that was sensitive to changes in the NADH/NAD(+) ratio. Hyperacetylation of mitochondrial malate-aspartate shuttle proteins impaired the transport and oxidation of cytosolic NADH in the mitochondria, resulting in altered cytosolic redox state and energy deficiency. Furthermore, acetylation of oligomycin-sensitive conferring protein at lysine-70 in adenosine triphosphate synthase complex promoted its interaction with cyclophilin D, and sensitized the opening of mitochondrial permeability transition pore. Both could be alleviated by normalizing the NAD(+) redox balance either genetically or pharmacologically. CONCLUSIONS: We show that mitochondrial protein hyperacetylation due to NAD(+) redox imbalance contributes to the pathologic remodeling of the heart via 2 distinct mechanisms. Our preclinical data demonstrate a clear benefit of normalizing NADH/NAD(+) imbalance in the failing hearts. These findings have a high translational potential as the pharmacologic strategy of increasing NAD(+) precursors are feasible in humans.
BACKGROUND: Impairments of mitochondrial function in the heart are linked intricately to the development of heart failure, but there is no therapy for mitochondrial dysfunction. METHODS: We assessed the reduced/oxidized ratio of nicotinamide adenine dinucleotide (NADH/NAD(+) ratio) and protein acetylation in the failing heart. Proteome and acetylome analyses were followed by docking calculation, mutagenesis, and mitochondrial calcium uptake assays to determine the functional role of specific acetylation sites. The therapeutic effects of normalizing mitochondrial protein acetylation by expanding the NAD(+) pool also were tested. RESULTS: Increased NADH/NAD(+) and protein hyperacetylation, previously observed in genetic models of defective mitochondrial function, also are present in human failing hearts as well as in mouse hearts with pathologic hypertrophy. Elevation of NAD(+) levels by stimulating the NAD(+) salvage pathway suppressed mitochondrial protein hyperacetylation and cardiac hypertrophy, and improved cardiac function in responses to stresses. Acetylome analysis identified a subpopulation of mitochondrial proteins that was sensitive to changes in the NADH/NAD(+) ratio. Hyperacetylation of mitochondrial malate-aspartate shuttle proteins impaired the transport and oxidation of cytosolic NADH in the mitochondria, resulting in altered cytosolic redox state and energy deficiency. Furthermore, acetylation of oligomycin-sensitive conferring protein at lysine-70 in adenosine triphosphate synthase complex promoted its interaction with cyclophilin D, and sensitized the opening of mitochondrial permeability transition pore. Both could be alleviated by normalizing the NAD(+) redox balance either genetically or pharmacologically. CONCLUSIONS: We show that mitochondrial protein hyperacetylation due to NAD(+) redox imbalance contributes to the pathologic remodeling of the heart via 2 distinct mechanisms. Our preclinical data demonstrate a clear benefit of normalizing NADH/NAD(+) imbalance in the failing hearts. These findings have a high translational potential as the pharmacologic strategy of increasing NAD(+) precursors are feasible in humans.
Authors: Li Yang; Bhavapriya Vaitheesvaran; Kirsten Hartil; Alan J Robinson; Michael R Hoopmann; Jimmy K Eng; Irwin J Kurland; James E Bruce Journal: J Proteome Res Date: 2011-08-16 Impact factor: 4.466
Authors: Tadahiro Shimazu; Matthew D Hirschey; Lan Hua; Kristin E Dittenhafer-Reed; Bjoern Schwer; David B Lombard; Yu Li; Jakob Bunkenborg; Frederick W Alt; John M Denu; Matthew P Jacobson; Eric Verdin Journal: Cell Metab Date: 2010-12-01 Impact factor: 27.287
Authors: Mounir Errami; Cristi L Galindo; Amina T Tassa; John M Dimaio; Joseph A Hill; Harold R Garner Journal: J Pharmacol Exp Ther Date: 2007-12-18 Impact factor: 4.030
Authors: Carles Cantó; Riekelt H Houtkooper; Eija Pirinen; Dou Y Youn; Maaike H Oosterveer; Yana Cen; Pablo J Fernandez-Marcos; Hiroyasu Yamamoto; Pénélope A Andreux; Philippe Cettour-Rose; Karl Gademann; Chris Rinsch; Kristina Schoonjans; Anthony A Sauve; Johan Auwerx Journal: Cell Metab Date: 2012-06-06 Impact factor: 27.287
Authors: Masaki Kajimoto; Dolena R Ledee; Nancy G Isern; Michael A Portman Journal: Am J Physiol Heart Circ Physiol Date: 2017-02-03 Impact factor: 4.733
Authors: Haobo Li; Margaret H Hastings; James Rhee; Lena E Trager; Jason D Roh; Anthony Rosenzweig Journal: Circ Res Date: 2020-02-13 Impact factor: 17.367
Authors: Nicolas Diguet; Samuel A J Trammell; Cynthia Tannous; Robin Deloux; Jérôme Piquereau; Nathalie Mougenot; Anne Gouge; Mélanie Gressette; Boris Manoury; Jocelyne Blanc; Marie Breton; Jean-François Decaux; Gareth G Lavery; István Baczkó; Joffrey Zoll; Anne Garnier; Zhenlin Li; Charles Brenner; Mathias Mericskay Journal: Circulation Date: 2017-12-07 Impact factor: 29.690
Authors: Angelical S Martin; Dennis M Abraham; Kathleen A Hershberger; Dhaval P Bhatt; Lan Mao; Huaxia Cui; Juan Liu; Xiaojing Liu; Michael J Muehlbauer; Paul A Grimsrud; Jason W Locasale; R Mark Payne; Matthew D Hirschey Journal: JCI Insight Date: 2017-07-20